Benegrastim

Drug Profile

Benegrastim

Alternative Names: F-627; rh G-CSF Fc Fusion Protein

Latest Information Update: 22 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Generon (Shanghai) Corporation
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Neutropenia

Most Recent Events

  • 23 Aug 2017 Generon (Shanghai) Corporation plans a phase III trial for Neutropenia (in patients with breast cancer) (NCT03252431)
  • 01 Aug 2016 Phase-III clinical trials in Neutropenia (Chemotherapy-induced) in USA (SC) (NCT02872103)
  • 18 Aug 2015 Benegrastim is still in phase-II development for Neutropenia (chemotherapy-induced) in Europe, USA and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top